Article info

Download PDFPDF

Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea

Authors

  1. Correspondence to Dr Nicole E Scangarella-Oman, GSK Collegeville, Collegeville, PA 19426, USA; nicole.e.scangarella-oman{at}gsk.com
View Full Text

Citation

Scangarella-Oman NE, Hossain M, Perry CR, et al
Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea

Publication history

  • Received May 5, 2022
  • Accepted September 30, 2022
  • First published November 21, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.